Latest Price of Ivosidenib (2026)

Ivosidenib can be used for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients who have received prior therapy. For such patients, conventional chemotherapy regimens often have limited efficacy, and disease control faces challenges. In contrast, the targeted drug ivosidenib provides an important treatment option for this patient population, helping to inhibit disease progression and improve treatment outcomes.

Latest Price of Ivosidenib (2026)

Currently, ivosidenib produced by Lucius Pharmaceutical Co., Ltd. is commonly available in a packaging specification of 250 mg × 60 tablets per box.

The market price of this drug is not a single fixed value; instead, it is comprehensively affected by multiple factors, resulting in a dynamically changing price range. These factors mainly include:

1. Regional differences (variations in pricing policies and market environments across different provinces and cities).

2. Medical insurance policies (whether the drug is included in national or local medical insurance lists, and the level of reimbursement ratio directly impact patients' out-of-pocket expenses).

3. Procurement channels (price differences may exist when purchasing through hospital pharmacies, designated retail pharmacies, or official cooperative channels).

4. Hospital grades (different tiers of hospitals implement varying standards for drug markups).

5. Market competition (the launch of similar or alternative drugs may affect pricing).

6.International exchange rate fluctuations (particularly significant for drugs with high dependence on imported raw materials or technologies).

When purchasing the drug, patients must refer to the price publicly posted by local medical institutions or licensed pharmacies at the time of purchase. It is recommended that patients in need of this medication contact the on-site dedicated customer service to inquire about real-time and accurate price information. Additionally, they can comprehensively assess the final actual medication costs by considering their personal insurance type, reimbursement thresholds, and ratios, so as to make sound financial plans for treatment.

What is the Mechanism of Action of Ivosidenib?

Ivosidenib is an oral small-molecule targeted anti-tumor drug classified as a tumor growth inhibitor. Its mechanism of action is highly specific: it primarily targets the abnormal protein produced by the mutated isocitrate dehydrogenase 1 (IDH1) gene. In healthy cells, the IDH1 protein participates in normal cellular metabolic processes. However, when the IDH1 gene undergoes specific mutations, it generates a mutant protein with oncogenic activity, which can promote the proliferation of tumor cells, block their differentiation, and maintain their malignant phenotype.

Ivosidenib can precisely recognize and selectively bind to this mutant protein, blocking its abnormal activity, thereby disrupting the growth signaling pathways of cancer cells and achieving the therapeutic goal of inhibiting or slowing the progression of leukemia. Compared with traditional chemotherapy, this targeted therapy directed against a well-defined oncogenic driver gene theoretically offers the advantages of more precise action and less damage to normal cells.

How to Take Ivosidenib?

Ivosidenib is available as an oral tablet. To ensure optimal drug absorption and efficacy, it must be administered strictly on an empty stomach. The specific fasting requirements are as follows: no food should be consumed for at least 2 hours before taking the medication, and food intake should also be avoided for at least 1 hour after administration; moderate water intake is permitted during this period.

When taking the tablets, they should be swallowed whole with a full glass of warm water. Chewing, crushing, or dissolving the tablets is strictly prohibited, as this may affect the drug's release characteristics and efficacy in the body.

Patients must take the daily dose exactly as prescribed by their physician. They must never arbitrarily increase or decrease the dosage on their own, to prevent insufficient efficacy or increased toxicity. During the course of treatment, if discontinuation is required due to special circumstances or a dose is missed, patients must first consult members of their medical team, such as the attending physician or pharmacist, and take corresponding measures under their professional guidance. Do not decide to make up the missed dose or skip it without authorization, so as to ensure the safety and continuity of treatment.